Business
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nAchieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year\n\nRecorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially\n\nEnded Q4 with over $71M in cash, generating $2M in cash in the fourth quarter\n\nProvides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range\n\nHosting conference call and webcast today at 8:30 a.m. ET\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance.\n\n“The Xeris team executed an exceptional 2024 with record revenue topping $203 million,” said John Shannon, Xeris’ Chief Executive Officer. “The continued momentum of our commercial business, our exciting pipeline, along with our unrelenting focus on execution will enable Xeris to create even more value for patients and shareholders.”\n\n“Xeris has never been financially stronger. Record quarterly revenue exceeding $60 million drove positive cash flow of $2 million in the fourth quarter and generated Adjusted EBITDA of over $8 million,” said Steven M. Pieper, Chief Financial Officer. “We expect 2025 total revenue of $255 to $275 million, which is over 30% growth at the mid-point. Further, we anticipate Adjusted EBITDA will remain positive going forward. Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris.”\n\n\n\nFourth Quarter 2024 Highlights\n\n\n\n\n\n \n\n\n\nThree months ended\nDecember 31,\n\n\n\n \n\n\n\nChange\n\n\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n2023\n\n\n\n \n\n\n\n$\n\n\n\n%\n\n\n\n\n\nProduct revenue (in thousands):\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nGvoke\n\n\n\n$\n\n\n\n23,262\n\n\n\n \n\n\n\n$\n\n\n\n18,639\n\n\n\n \n\n\n\n$\n\n\n\n4,623\n\n\n\n \n\n\n\n24.8\n\n\n\n \n\n\n\n\n\nRecorlev\n\n\n\n \n\n\n\n22,614\n\n\n\n \n\n\n\n \n\n\n\n9,806\n\n\n\n \n\n\n\n \n\n\n\n12,808\n\n\n\n \n\n\n\n130.6...